NEW YORK (GenomeWeb News) – OncoMethylome Sciences has inked a worldwide non-exclusive agreement granting Qiagen rights to use certain of its methylation technologies in future Qiagen products, the Liege, Belgium-based firm said today.
 
The firms anticipate that these future products will expand, among others, Qiagen’s EpiTect product line. Specifically, the agreement covers OncoMethylome Sciences’ methylation-specific PCR technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.